Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Pain and Headache Reports
Erschienen in: Current Pain and Headache Reports 5/2018

01.05.2018 | Childhood and Adolescent Headache (S Evers, Section Editor)

The Evidence for the Role of Nutraceuticals in the Management of Pediatric Migraine: a Review

verfasst von: Serena L. Orr

Erschienen in: Current Pain and Headache Reports | Ausgabe 5/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Nutraceuticals are a form of complementary and alternative medicine that is commonly used by children and adolescents with migraine. In this review, observational studies, randomized controlled trials, systematic reviews, and meta-analyses on the efficacy and safety of single compound nutraceuticals for the management of migraine in children and adolescents were identified through a literature search of MEDLINE, Embase, and EBM Reviews—Cochrane Central Register of Controlled Trials.

Recent Findings

Twenty-one studies were reviewed, of which 11 were observational studies, 7 were randomized controlled trials, and 3 were systematic reviews. Six different nutraceuticals were included in the review: vitamin D, riboflavin, coenzyme Q10, magnesium, butterbur, and polyunsaturated fatty acids. All but three of the studies assessed the role of nutraceuticals in migraine prevention, while three studies evaluated the role of intravenous magnesium for acute migraine management. Overall, the quality and size of the studies were limited.

Summary

Due to low quality evidence and limited studies, no definite conclusions can be drawn on the efficacy of nutraceuticals for the treatment of pediatric migraine. Future studies are warranted in order to establish evidence upon which to define the role of nutraceuticals in this patient population.
Literatur
1.
Abu-Arafeh I, Razak S, Sivaraman B, Graham C. Prevalence of headache and migraine in children and adolescents: a systematic review of population-based studies. Dev Med Child Neurol. 2010;52(12):1088–97.CrossRefPubMed
2.
Feigin VL, Abajobir AA, Abate KH, Abd-Allah F, Abdulle AM, Abera SF, et al. Global, regional, and national burden of neurological disorders during 1990–2015: a systematic analysis for the global burden of disease study 2015. Lancet Neurol. 2017;16:877–97.CrossRef
3.
El-Chammas K, Keyes J, Thompson N, Vijayakuman J, Becher D, Jackson J. A comparative effectiveness meta-analysis of drugs for the prophylaxis of pediatric migraine headache. JAMA Pediatr. 2013;167(3):250–8.CrossRefPubMedPubMedCentral
4.
Shamliyan T, Kane R, Ramakrishnan R, Taylor F. Migraine in children: preventive pharmacologic treatments. Rockv Agency Healthc Res Qual. 2013;28(108):1225–37.
5.
Lai LL, Koh L, Ho JA-C, Ting A, Obi A. Off-label prescribing for children with migraines in US ambulatory care settings. J Manag Care Spec Pharm. 2017;23(3):382–7.CrossRefPubMed
6.
•• Powers SW, Coffey CS, Chamberlin LA, Ecklund DJ, Klingner EA, Yankey JW, et al. Trial of amitriptyline, topiramate, and placebo for pediatric migraine. N Engl J Med. 2017;376(2):115–24. The CHAMP study is the highest quality pediatric migraine prevention trial to date. CrossRefPubMed
7.
Hershey AD, Powers SW, Coffey CS, Eklund DD, Chamberlin LA, Korbee LL. Childhood and adolescent migraine prevention (CHAMP) study: a double-blinded, placebo-controlled, comparative effectiveness study of amitriptyline, topiramate, and placebo in the prevention of childhood and adolescent migraine. Headache. 2013;53(5):799–816.CrossRefPubMedPubMedCentral
8.
Evers S, Marziniak M, Frese A, Gralow I. Placebo efficacy in childhood and adolescence migraine: an analysis of double-blind and placebo-controlled studies. Cephalalgia. 2009;29(4):436–44.CrossRefPubMed
9.
Kalra EK. Nutraceutical-definition and introduction. AAPS PharmSciTech. 2003;5(3):E25.
10.
Dalla Libera D, Colombo B, Pavan G, Comi G. Complementary and alternative medicine (CAM) use in an Italian cohort of pediatric headache patients: the tip of the iceberg. Neurol Sci. 2014;35(S1):145–8.CrossRefPubMed
11.
Bethell C, Kemper KJ, Gombojav N, Koch TK. Complementary and conventional medicine use among youth with recurrent headaches. Pediatrics. 2013;132(5):e1173–83.CrossRefPubMedPubMedCentral
12.
• Groenewald CB, Beals-Erickson SE, Ralston-Wilson J, Rabbitts JA, Palermo TM. Complementary and alternative medicine use by children with pain in the United States. Acad Ped. 2017;17(7):785–93. This study highlights the prevalence of complementary and alternative medicine use amongst children and adholescents with headache and other pain conditions. CrossRef
13.
Kenney D, Jenkins S, Youssef P, Kotagal S. Patient use of complementary and alternative medicines in an outpatient pediatric neurology clinic. Pediatr Neurol. 2016;58:48–52.e7.CrossRefPubMed
14.
Di Somma C, Scarano E, Barrea L, Zhukouskaya VV, Savastano S, Mele C, et al. Vitamin D and neurological diseases: an endocrine view. Int J Mol Sci. 2017;18(11):1–26.CrossRef
15.
Potrykus A, Pilarska F. The role of vitamin D supply and its impact on headaches in children and teenagers. Eur J Paediatr Neurol. 2013;17:S81.CrossRef
16.
Cayir A, Turan MI, Tan H. Effect of vitamin D therapy in addition to amitriptyline on migraine attacks in pediatric patients. Braz J Med Biol Res. 2014;47(4):349–54.CrossRefPubMedPubMedCentral
17.
Vogiatzi MG, Jacobson-Dickman E, DeBoer MD. Vitamin D supplementation and risk of toxicity in pediatrics: a review of current literature. J Clin Endocrinol Metab. 2014;99(4):1132–41.CrossRefPubMed
18.
Reyngoudt H, Paemeleire K, Descamps B, De Deene Y, Achten E. 31P-MRS demonstrates a reduction in high-energy phosphates in the occipital lobe of migraine without aura patients. Cephalalgia. 2011;31(12):1243–53.CrossRefPubMed
19.
Lodi R, Lotti S, Cortelli P, Pierangeli G, Cevoli S, Clementi V, et al. Deficient energy metabolism is associated with low free magnesium in the brains of patients with migraine and cluster headache. Brain Res Bull. 2001;54(4):437–41.CrossRefPubMed
20.
Okada H, Araga S, Takeshima T, Nakashima K. Plasma lactic acid and pyruvic acid levels in migraine and tension-type headache. Headache. 1998;38:39–42.CrossRefPubMed
21.
Lodi R, Kem GJ, Mon P, Pierangeli G, Cor P, Iot S. Quantitative analysis of skeletal muscle bioenergetics and proton efflux in migraine and cluster headache. J Neurol Sci. 1997;146(1):73–80.CrossRefPubMed
22.
Lodi R, Motagna P, Soriani S, Iotti S, Arnaldi C, Cortelli P, et al. Deficit of brain and skeletal muscle bioenergetics and low brain magnesium in juvenile migraine: an in vivo 31 P magnetic resonance spectroscopy interictal study. Pediatr Res. 1997;42:866–71.CrossRefPubMed
23.
Sangiorgi S, Mochi M, Riva R, Cortelli P, Monari L, Pierangeli G, et al. Abnormal platelet mitochondrial function in patients affected by migraine with and without aura. Cephalalgia. 1994;14(1):21–3.CrossRefPubMed
24.
Barbiroli B, Montagna P, Cortelli P, Funicello R, Iotti S, Monari L, et al. Abnormal brain and muscle energy metabolism shown by 31P magnetic resonance spectroscopy in patients affected by migraine with aura. Neurology. 1992;42(6):1209–14.CrossRefPubMed
25.
Montagna P, Sacquegna T, Martinelli P, Cortelli P, Bresolin N, Moggio M, et al. Mitochondrial abnormalities in migraine. Preliminary findings. Headache. 1988;28(7):477–80.CrossRefPubMed
26.
Younis S, Hougaard A, Vestergaard MB, Larsson HBW, Ashina M. Migraine and magnetic resonance spectroscopy: a systematic review. Curr Opin Neurol. 2017;30(3):246–62.CrossRefPubMed
27.
Taylor FR. Nutraceuticals and headache: the biological basis. Headache. 2011;51(3):484–501.CrossRefPubMed
28.
Markley H. Prophylactic treatment of headaches in adolescents with riboflavin. Cephalalgia. 2009;29(S1):100.
29.
30.
MacLennan SC, Wade FM, Forrest KML, Ratanayake PD, Fagan E, Antony J. High-dose riboflavin for migraine prophylaxis in children: a double-blind, randomized, placebo-controlled trial. J Child Neurol. 2008;23(11):1300–4.CrossRefPubMed
31.
Bruijn J, Duivenvoorden H, Passchier J, Locher H, Dijkstra N, Arts W-F. Medium-dose riboflavin as a prophylactic agent in children with migraine: a preliminary placebo-controlled, randomised, double-blind, cross-over trial. Cephalalgia. 2010;30(12):1426–34.CrossRefPubMed
32.
• Namazi N, Heshmati J, Tarighat-Esfanjani A. Supplementation with riboflavin (vitamin B2) for migraine prophylaxis in adults and children: a review. Int J Vitam Nutr Res. 2015;85(1–2):79–87. This systematic review addresses the conclusions that can be drawn from the available data on riboflavin for migraine treatment. CrossRefPubMed
33.
• Thompson DF, Saluja HS. Prophylaxis of migraine headaches with riboflavin: a systematic review. J Clin Pharm Ther. 2017;42(4):394–403. This systematic review addresses the conclusions that can be drawn from the available data on riboflavin for migraine treatment. CrossRefPubMed
34.
Dahri M, Tarighat-Esfanjani A, Asghari-Jafarabadi M, Hashemilar M. Oral coenzyme Q10 supplementation in patients with migraine: effects on clinical features and inflammatory markers. Nutr Neurosci. 2018 1–9.
35.
•• Goadsby PJ, Reuter U, Hallström Y, Broessner G, Bonner JH, Zhang F, et al. A controlled trial of erenumab for episodic migraine. N Engl J Med. 2017;377(22):2123–32. This is one of the two initial published randomized controlled trials assessing the efficacy and safety of CGRP receptor antagonists for migraine prevention in adults. CrossRefPubMed
36.
•• Silberstein SD, Dodick DW, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, et al. Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med. 2017;377(22):2113–22. This is one of the two initial published randomized controlled trials assessing the efficacy and safety of CGRP receptor antagonists for migraine prevention in adults. CrossRefPubMed
37.
Wrobel Goldberg S, Silberstein SD. Targeting CGRP: a new era for migraine treatment. CNS Drugs. 2015;29(6):443–52.CrossRefPubMed
38.
Hershey AD, Powers SW, A-LB V, Lecates SL, Ellinor PL, Segers A, et al. Coenzyme Q10 deficiency and response to supplementation in pediatric and adolescent migraine. Headache. 2007;47(1):73–80.CrossRefPubMed
39.
Slater SK, Nelson TD, Kabbouche MA, LeCates SL, Horn P, Segers A, et al. A randomized, double-blinded, placebo-controlled, crossover, add-on study of CoEnzyme Q10 in the prevention of pediatric and adolescent migraine. Cephalalgia. 2011;31(8):897–905.CrossRefPubMed
40.
Gallai V, Sarchielli P, Coata G, Firenza C, Morucci P, Abbritti G. Serum and salivary magnesium levels in migraine: results in a group of juvenile patients. Headache. 1992;32(2):132–5.CrossRefPubMed
41.
Soriani S, Arnaldi C, DeCarlo L, Arcudi D, Mazzotta D, Battistella PA, et al. Serum and red blood cell magnesium levels in juvenile migraine patients. Headache. 1995;35(1):14–6.CrossRefPubMed
42.
Aloisi P, Marrelli A, Porto C, Tozzi E, Cerone G. Visual evoked potentials and serum magnesium levels in juvenile migraine patients. Headache. 1997;37(6):383–5.CrossRefPubMed
43.
Martinez Cardenas V, Rodriguez M, Burke M, Vasconcellos E. Efficacy and safety of intravenous magnesium sulfate treatment in pediatric patients with headaches. Headache. 2012;52(5):896.
44.
Gertsch EA, Loharuka S, Wolter-Warmerdam KG, Tong S, Kedia S. Intravenous magnesium as abortive treatment for headaches in children. Ann Neurol. 2011;Conference(var.pagings):S167.
45.
• Patniyot IR, Gelfand AA. Acute treatment therapies for pediatric migraine: a qualitative systematic review. Headache. 2016;56(1):49–70. This is a recent systematic review on the efficacy of acute interventions for pediatric migraine. CrossRefPubMed
46.
Castelli S, Meossi C, Domenici R, Fontana F, Stefani G. Magnesium in the prophylaxis of primary headache and other periodic disorders in children. Pediatr Med Chir. 1993;15(5):481–8.PubMed
47.
Gallelli L, Avenoso T, Falcone D, Palleria C, Peltrone F, Esposito M, et al. Effects of acetaminophen and ibuprofen in children with migraine receiving preventive treatment with magnesium. Headache. 2014;54(2):313–24.CrossRefPubMed
48.
Wang F, Van Den Eeden SK, Ackerson LM, Salk SE, Reince RH, Elin RJ. Oral magnesium oxide prophylaxis of frequent migrainous headache in children: a randomized, double-blind, placebo-controlled trial. Headache. 2003;43(6):601–10.CrossRefPubMed
49.
Sadler C, Vanderkagt L, Vohra S. Complementary, holistic and integrative medicine: butterbur. Pediatr Rev. 2007;28:235–8.CrossRefPubMed
50.
Holland S, Silberstein SD, Freitag F, Dodick DW, Argoff C, Ashman E. Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012;78(17):1346–53.CrossRefPubMedPubMedCentral
51.
Pringsheim T, Davenport W, Mackie G, Worthington I, Aube M, Christie S, et al. Canadian headache society guideline for migraine prophylaxis. Can J Neurol Sci. 2012;39(S2):1–62.
52.
Orr SL. Diet and nutraceutical interventions for headache management: a review of the evidence. Cephalalgia. 2016;36(12):1112–33.CrossRefPubMed
53.
• Rajapakse T, Pringsheim T. Nutraceuticals in migraine: a summary of existing guidelines for use. Headache. 2016;56(4):808–16. This is a summary statement that describes the various guidelines for the use of nutraceuticals in migraine. CrossRefPubMed
54.
Mauskop A. Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2013;80(9):868–9.CrossRefPubMed
55.
Fiebich B, Grozdeva M, Hess S, Hüll M, Danesch U, Bodensieck A, et al. Petasites hybridus extracts in vitro inhibit COX-2 and PGE2 release by direct interaction with the enzyme and by preventing p42/44 MAP kinase activation in rat primary microglial cells. Planta Med. 2005;71(1):12–9.CrossRefPubMed
56.
Wang G, Shum A, Lin Y, Liao J, Wu X, Ren J, et al. Calcium channel blockade in vascular smooth muscle cells: major hypotensive mechanism of S-petasin, a hypotensive sesquiterpene from Petasites formosanus. J Pharmacol Exp Ther. 2001;297(1):240–6.PubMed
57.
Pothmann R, Danesch U. Migraine prevention in children and adolescents: results of an open study with a special butterbur root extract. Headache. 2005;45(3):196–203.
58.
Oelkers-Ax R, Leins A, Parzer P, Hillecke T, Bolay HV, Fischer J, et al. Butterbur root extract and music therapy in the prevention of childhood migraine: an explorative study. Eur J Pain. 2008;12(3):301–13.CrossRefPubMed
59.
Avula B, Wang Y-H, Wang M, Smillie TJ, Khan IA. Simultaneous determination of sesquiterpenes and pyrrolizidine alkaloids from the rhizomes of Petasites hybridus (L.) G.M. et Sch. and dietary supplements using UPLC-UV and HPLC-TOF-MS methods. J Pharm Biomed Anal. 2012;70:53–63.CrossRefPubMed
60.
Danesch U, Rittinghausen R. Safety of a patented special butterbur root extract for migraine prevention. Headache. 2003;43(1):76–8.CrossRefPubMed
61.
Prieto JM. Update on the efficacy and safety of Petadolex®, a butterbur extract for migraine prophylaxis. Bot Targets Ther. 2014;4:1–9.
62.
Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S. Pathophysiology of migraine: a disorder of sensory processing. Physiol Rev. 2017;97(2):553–622.CrossRefPubMedPubMedCentral
63.
Simopoulos A. Omega-3 fatty acids in inflammation and autoimmune diseases. J Am Coll Nutr. 2002;21(6):495–505.CrossRefPubMed
64.
Sadeghi O, Maghsoudi Z, Khorvash F, Ghiasvand R, Askari G. The relationship between different fatty acids intake and frequency of migraine attacks. Iran J Nurs Midwifery Res. 2015;20(3):334–9.PubMedPubMedCentral
65.
Fayyazi A, Khajeh A, Ghazavi A, Sangestani M. Omega 3 in childhood migraines: a double blind randomized clinical trial. Iran J Child Neurol. 2016;10(1):14–21.
66.
•• Le K, Yu D, Wang J, Ali AI, Guo Y. Is topiramate effective for migraine prevention in patients less than 18 years of age? A meta-analysis of randomized controlled trials. J Headache Pain. 2017;18(1):69. This is a systematic review and meta-analysis that pooled all of the evidence for topiramate in pediatric migraine prevention. CrossRefPubMedPubMedCentral
67.
Job K, Kiang T, Constance J, Sherwin C, Enioutina E. Herbal medicines: challenges in the modern world. Part 4. Canada and United States. Expert Rev Clin Pharmacol. 2016;9(12):1597–609.CrossRefPubMed
68.
Snyder FJ, Dundas ML, Kirkpatrick C, Neill KS. Use and safety perceptions regarding herbal supplements: a study of older persons in southeast Idaho. J Nutr Elder. 2009;28(1):81–95.CrossRefPubMed
Metadaten
Titel
The Evidence for the Role of Nutraceuticals in the Management of Pediatric Migraine: a Review
verfasst von
Serena L. Orr
Publikationsdatum
01.05.2018
Verlag
Springer US
Erschienen in
Current Pain and Headache Reports / Ausgabe 5/2018
Print ISSN: 1531-3433
Elektronische ISSN: 1534-3081
DOI
https://doi.org/10.1007/s11916-018-0692-6

Weitere Artikel der Ausgabe 5/2018

Current Pain and Headache Reports 5/2018 Zur Ausgabe

Chronic Daily Headache (S.J. Wang, Section editor)

CGRP Monoclonal Antibodies for the Preventative Treatment of Migraine

Other Pain (A Kaye and N Vadivelu, Section Editors)

New Advances in Acute Postoperative Pain Management

Other Pain (A Kaye and N Vadivelu, Section Editors)

Evidence-Based Non-Pharmacological Therapies for Fibromyalgia

Migraine and Beyond (R Cowan, Section Editor)

Is Migraine Primarily a Metaboloendocrine Disorder?

Other Pain (A Kaye and N Vadivelu, Section Editors)

America’s Opioid Epidemic: a Comprehensive Review and Look into the Rising Crisis

Other Pain (A Kaye and N Vadivelu, Section Editors)

Global Supply and Demand of Opioids for Pain Management

Neu im Fachgebiet AINS

23.04.2024 | Appendizitis | Nachrichten

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 | Leitsymptom Rückenschmerzen | Nachrichten

Ärztliche Empathie hilft gegen Rückenschmerzen

23.04.2024 | Operationsvorbereitung | Nachrichten

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

23.04.2024 | Pankreaskarzinom | Nachrichten

S3-Leitlinie zu Pankreaskrebs aktualisiert
weitere anzeigen

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

hier abonnieren